Former FDA leaders, pharma speak out on mifepristone - Takeaways - MDSpire

Former FDA leaders, pharma speak out on mifepristone

  • By

  • Theresa Gaffney

  • May 8, 2026

  • 0 min

Share

  • 1

    The Supreme Court's decision on mifepristone regulation could significantly affect the FDA's authority and abortion access in the U.S.

  • 2

    States can regulate abortion, but the FDA's removal of in-person dispensing for mifepristone has increased access to the medication.

  • 3

    Former FDA leaders argue that the agency's cautious approach to mifepristone regulation is based on sound science and should be upheld.

  • 4

    Louisiana claims the FDA's decision violates the Administrative Procedure Act and the Comstock Act, challenging the legality of mail orders.

  • 5

    If the Supreme Court sides with the 5th Circuit, enforcing new restrictions on mifepristone could complicate access to abortion medications.

Original Source(s)

Former FDA leaders, pharma speak out on mifepristone

  • by Theresa Gaffney

  • May 8, 2026

Related Content

Women’s Engagement With Different Internet-Enabled Technologies to Access Digital Menopause Information: Mixed Methods, Multiphase Sequential Study

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.